Brief: VBL Therapeutics Treats First Patient In Phase 2 Randomized Controlled Study Of VB-201 In Covid-19 Patients
27/01/2021 12:10
Jan 27 (Reuters) - Vascular Biogenics Ltd VBLT.O :
* VBL THERAPEUTICS TREATS FIRST PATIENT IN PHASE 2
RANDOMIZED
CONTROLLED STUDY OF VB-201 IN COVID-19 PATIENTS
Source text for Eikon: ID:nGNX9V7Z2y
Further company coverage: VBLT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Notable Labs
See all newsUS STOCKS-Wall St ends sharply lower following Trump's anti-Powell tirade
US STOCKS-Wall St ends sharply lower amid Trump's tirade against Fed's Powell
US STOCKS-Wall St tumbles as Trump ramps up tirade against Fed's Powell
Brief: Notable Labs Says Co, Units Filed Voluntary Petition Under Provisions Of Chapter 7 Of Title 11 Of US Bankruptcy Code
Brief: Notable Labs Approved A Streamlined Operating Plan Which Includes Exploring Strategic Alternatives